Accession Therapeutics’ elegant Trocept platform has potential to treat some of the most intractable and widespread forms of cancer. Based in Oxford, UK, it is developing a pipeline of products to the early clinical trial stage. Led by Bent Jakobsen, PhD FMedSci, a pioneer of T cell receptor therapy for cancer, the team is highly experienced intaking immuno-oncology products to the clinic. Accession Therapeutics’ Trocept technology is based on over a decade’s work and has generated exceptional preclinical data.Accession Therapeutics’ proprietary technology incorporates cancer-tropic viruses, the first time that viruses have been genetically modified to exclusively target cancer cells.As non-cancerous cells are not targeted by Trocept, systemic toxicity is eliminated meaning the drugs can be delivered intravenously and traffic to the tumour.Trocept’s highly potent and local activity gives it potential in some of the hardest to treat and most widespread forms of cancer. This includes breast, cervical, colorectal, gastric, head and neck, lung, oral, ovarian and pancreatic cancer.

Biotechnology

Accession Therapeutics Limited

Bent Jakobsen

Stephanie Smith Bewick

Tony Hinton

Rita Figueiredo

Lok Hang Mak

Johanne Pentier, Ph. D.

Jez (Andrew) Gerry

Andy Johnson

Alan Parker

Scientific Research Team

Clinical and Quality Operations

Leadership Team

��

Teams at Accession Therapeutics Limited

Scientific Research Team

Clinical and Quality Operations

Leadership Team

��������

Teams at Accession Therapeutics Limited

Scientific Research Team

Clinical and Quality Operations

Leadership Team

��